On a map of global climate tech, Zanzibar is not a typical pin. It is an archipelago known for spice farms and fishing dhows, not biopolymer labs. But for Lavine Irvine, a data scientist who has worked at GSK and BMW, it is the only place that made sense for Coastal Biotech. Her startup is trying to turn the island’s abundant seaweed into a suite of agricultural products, from organic biostimulants to crop protectants, and sell them back to local farmers and global manufacturers. The unit economics of climate adaptation, she seems to argue, start with a local feedstock.
A fully integrated bet on macroalgae
Most early-stage ag-biotech companies pick a lane. They might develop a novel compound, or they might focus on scaling production of a known one. Coastal Biotech is attempting to do it all, from R&D to contract manufacturing, under one roof in Zanzibar. The company’s public positioning describes it as a “fully integrated manufacturer” of premium agricultural products derived from marine plants. Its planned product slate is broad, organized into three buckets that each target a different slice of the $200 billion-plus global market for agricultural inputs.
- Biostimulants and crop protectants. These are organic, seaweed-based alternatives to synthetic fertilizers and pesticides, designed to help plants withstand heat, drought, and other climate stresses. This is the most immediate wedge into the small-scale farming communities around Zanzibar.
- Food and feed ingredients. Here, processed macroalgae becomes a functional ingredient for human food and animal feed, tapping into growing demand for sustainable additives.
- Bio-materials. The longest-term play involves developing biopolymers and other algae-based materials for industrial applications, with an offer of contract manufacturing and technology licensing for clients.
The integrated model is ambitious. It suggests Coastal Biotech wants to control the entire value chain from seaweed cultivation to finished product, capturing more margin and ensuring quality. It also means the company is trying to build a factory, a lab, and a sales channel simultaneously.
Why Zanzibar, and why now?
The bet hinges on a local resource. Zanzibar already has an established seaweed farming sector, primarily for the carrageenan extract used as a thickener in foods and cosmetics. Coastal Biotech aims to move up the value chain from that commodity base. By sourcing locally, the company avoids import costs and complex supply chains, and it can build a narrative of community economic development alongside carbon-negative operations. The timing aligns with a global push for nature-based solutions and bio-based alternatives to petroleum-derived chemicals. For East African farmers facing increasingly erratic weather, a locally made, climate-resilient input could be both practical and affordable.
The team, while small, is built for this dual challenge of deep tech and local operations. CEO Lavine Irvine brings an analytical, operational background from multinational corporations [NextCapital, retrieved 2026]. Danford Mkunda, focused on R&D, adds a biochemical specialization in biopolymers and higher-value compounds [Munich Startup, retrieved 2026]. The company’s recruitment of a specialized Seaweed Biotechnologist points to a serious commitment to the science underlying the product claims.
The risks of a three-front war
For all its elegant logic, Coastal Biotech’s integrated model is a high-wire act for a pre-seed company. The public record shows participation in the SAIS Accelerator but no disclosed equity funding rounds, suggesting a reliance on grants, bootstrapping, or non-dilutive capital [SAIS Accelerator, retrieved 2026]. Building a biomanufacturing facility is capital-intensive. The company is also targeting three distinct customer segments,subsistence farmers, B2B ingredient buyers, and industrial biomaterial clients,each with its own sales motion and proof requirements. While the company claims its operations are carbon-negative, specific, verifiable data on lifecycle emissions or long-term offtake agreements with buyers are not yet public. Success will require excelling at biotechnology, scaled manufacturing, and grassroots agricultural extension all at once.
What to watch in the next 18 months
The company’ near-term milestones are physical and financial. The construction and commissioning of its planned seaweed fertilizer factory will be the first major proof point of its integrated model. Following that, the first announced commercial contract, particularly in the B2B bio-materials segment, would validate demand beyond the local farm gate. Finally, a priced equity round would signal investor belief in the capital plan and provide the fuel for the next phase of R&D and scale.
On the back of an envelope, the potential is tangible. If Coastal Biotech can convert one hectare of Zanzibar’s seaweed harvest into biostimulants, it could displace several hundred kilograms of synthetic nitrogen fertilizer, avoiding the associated manufacturing emissions and runoff. The real test, however, won’t be in a lab report. It will be in the fields, where the company must prove its products can reliably beat the incumbent,the cheap, familiar, and chemically potent bag of synthetic fertilizer that has defined global agriculture for decades.
Sources
- Sonar Pro Brief on Coastal Biotech
- [SAIS Accelerator, retrieved 2026] Coastal Biotech - SAIS Accelerator | https://sais-accelerator.com/start-up-profile/coastal-biotech/
- [NextCapital, retrieved 2026] Coastal Biotech - by Sheriff Alimi and Aisha Aliu | https://nextcapital.substack.com/p/coastal-biotech
- [Munich Startup, retrieved 2026] Coastal Biotech - Munich Startup | https://www.munich-startup.de/en/startups/coastal-biotech/